At the forefront of therapies for rare and orphan diseasesTM
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events

Home >> Investor Relations >> Investor Relations

Investor Relations

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

View all »Recent Releases

Dec 11, 2014
Amicus Therapeutics to Submit European Marketing Application for Migalastat Monotherapy for Fabry Disease

Dec 4, 2014
Amicus Therapeutics to Present at Oppenheimer Healthcare Conference

View all »Events & Presentations

Dec 11, 2014 at 1:35 PM ET
Oppenheimer Healthcare Conference

Nov 15, 2014 at 10:00 AM ET
American Society of Nephrology (ASN) – Migalastat Monotherapy Phase 3 Data

Copyright © 2014 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy